Sugi Predict
/ Targets
/ MAGT1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to MAGT1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Evaluating the Safety and Efficacy of Decitabine in the Treatment of XMEN Patients |
PHASE4 | NOT_YET_RECRUITING |
| A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease |
PHASE4 | COMPLETED |
| OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease |
PHASE2 | COMPLETED |
| A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis |
PHASE1/PHASE2 | RECRUITING |
| Vaccine Treatment for Advanced Non-Small Cell Lung Cancer |
PHASE1/PHASE2 | COMPLETED |
| 24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG |
PHASE2 | COMPLETED |
| Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses |
PHASE2 | COMPLETED |
| Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients |
PHASE2 | ENROLLING_BY_INVITATION |
| Vaccine Treatment for Surgically Resected Pancreatic Cancer |
PHASE1/PHASE2 | COMPLETED |
| Hereditary Sensory Neuropathy Serine Trial |
PHASE2 | UNKNOWN |
| GM1 Ganglioside Effects on Parkinson's Disease |
PHASE2 | COMPLETED |
| A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases |
PHASE1 | COMPLETED |
| Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects |
PHASE1 | UNKNOWN |
| Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) |
nan | WITHDRAWN |
| Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy |
nan | UNKNOWN |
| Glycosylation in Patients With Galactosaemia |
nan | COMPLETED |
| Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) |
nan | WITHDRAWN |
| The Natural History of Alpha-Mannosidosis |
nan | COMPLETED |
| Registry Gangliosidoses |
nan | UNKNOWN |
| Canadian Fabry Disease Initiative (CFDI) National Registry |
nan | RECRUITING |
| Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders |
nan | RECRUITING |
| Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation |
nan | COMPLETED |
| Biomarker for Mannosidosis Disease (BioMannosidosis) |
nan | WITHDRAWN |
| Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease |
nan | COMPLETED |
| Characterizing the Retinal Microvasculature in Patients with Fabry Disease: a Prospective Observational Study |
nan | RECRUITING |
| Evaluation of Blood Protein O-GlcNAcylation Levels in Children |
nan | RECRUITING |
| A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease |
nan | COMPLETED |
| Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children |
nan | RECRUITING |
| Chinese PD-GBA Registry |
nan | RECRUITING |
Related proteins — ESM-2 sequence neighbours (a MAGT1 binder may also engage these)